Vanda Pharmaceuticals Inc. Phase II Study Shows Investigational Insomnia Agent VEC-162 Improved Key Sleep Measures

... Results from a phaseII study presented this week demonstrated the effects of VEC-162 in a modelof transient insomnia on the traditional measures of sleep onset andmaintenance. VEC-162, an investigational agent under clinical developmentby Vanda Pharmaceuticals for the treatment of insomnia, is a novelmelatonin agonist. [click link for full article] ...